Angelova PR, Abramov AY (2018) Role of mitochondrial ROS in the brain: from physiology to neurodegeneration
The more cautious interpretation is that patients who receive GLP-1 receptor agonists may differ in important but incompletely measured ways from those treated with insulin or metformin, including overall health, treatment access, healthcare follow-up, or cardiometabolic care intensity
June 2011
The importance of this finding is highlighted by the fact that GWAS utilizes a less biased approach by first detecting, among a large pool of candidate SNPs, those SNPs that strongly correlate with disease risk or progression
This disconnect underscores ongoing questions about prioritisation and access
The metabolic changes supported by postbiotics, chromium, and botanical extracts take time to accumulate